Zimmer Biomet Holdings Inc (ZBH) Position Lifted by D.A. Davidson & CO.
D.A. Davidson & CO. increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 5.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,350 shares of the medical equipment provider’s stock after acquiring an additional 862 shares during the quarter. D.A. Davidson & CO.’s holdings in Zimmer Biomet were worth $2,094,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of ZBH. Bank of Nova Scotia Trust Co. purchased a new position in Zimmer Biomet in the 3rd quarter worth about $112,000. FNY Managed Accounts LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth about $117,000. Cerebellum GP LLC purchased a new position in Zimmer Biomet in the 4th quarter worth about $133,000. Steward Partners Investment Advisory LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth about $140,000. Finally, Chesley Taft & Associates LLC purchased a new position in Zimmer Biomet in the 4th quarter worth about $202,000. 86.36% of the stock is currently owned by institutional investors.
In other news, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.07% of the stock is currently owned by company insiders.
Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $120.48 on Monday. Zimmer Biomet Holdings Inc has a 1-year low of $108.03 and a 1-year high of $133.49. The firm has a market cap of $24,393.95, a PE ratio of 13.37, a PEG ratio of 2.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the business earned $2.14 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. sell-side analysts predict that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is currently 10.65%.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-position-lifted-by-d-a-davidson-co/1875827.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.